Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01861717 : A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.
PhasePhase 4
AgesMin: 18 Years Max: 75 Years
Inclusion Criteria:

- age 18 - 75

- elevated serum IGF-1 level above age- and sex-based normal values and failure of
growth hormone(GH) suppression to < 1.0 ng/ml after a 75 gm oral glucose tolerance
test (OGTT) American Association of Clinical Endocrinolgists (AACE) Acromegaly
Clinical Guidelines 2004

- visible pituitary adenoma (microadenoma or macroadenoma) on high quality pituitary
MRI without and with gadolinium

- prior treatments for acromegaly with surgery, somatostatin analogs or pegvisomant are
acceptable if these therapies have been discontinued for at least 3 months prior to
study entry

Exclusion Criteria:

- Age < 18 or > 75 years

- acromegalic patients currently on a lanreotide or octreotide preparation or on

- patients who have received prior radiotherapy or radiosurgery

- patients with adenoma-related visual acuity or visual field deficit from optic nerve
and/or chiasm compression or severe optic nerve/chiasm compression in the setting of
normal visual fields and acuity

- patients with pituitary apoplexy defined as recent tumor hemorrhage and/or infarction
on MRI with associated symptoms of new onset visual loss, diplopia and/or adrenal
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557